Abstract
Disturbed metabolism as a consequence of obesity and diabetes may cause cardiac diseases (recently highlighted in the CVR spotlight issue on Metabolic cardiomyopathies).1 In turn, the metabolism of the heart may also be disturbed in genetic and acquired forms of hypertrophic cardiac disease. Here, we provide an overview of recent insights on metabolic changes in genetic hypertrophic cardiomyopathy (HCM) and discuss several therapies which may be explored to target disturbed metabolism and prevent onset of cardiac hypertrophy.
Original language | English |
---|---|
Pages (from-to) | 1273-1280 |
Number of pages | 8 |
Journal | Cardiovascular Research |
Volume | 114 |
Issue number | 10 |
Early online date | 15 Jun 2018 |
DOIs | |
Publication status | Published - 1 Aug 2018 |
Bibliographical note
JV is supported by the Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation, CVON2014-40 DOSIS. SH has received funding from the European Union Commission’s Seventh Framework programme under grant agreement N° 305507 (HOMAGE), N° 602904 (FIBROTARGETS) and FP7-Health-2013- Innovations-1 N° 602156 (HECATOS). . We acknowledge the support from the Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation, CVON2011-ARENA, CVON2016-Early HFPEF, and ShePREDICTS. This research is cofinanced as a PPP-allowance Research and Innovation by the Ministry of Economic Affairs within Top Sector Life sciences & Health. This research was co-funded by the C3 project “Vision Core Leuven” of the Leuven UniversityKeywords
- Journal Article
- hypertrophic cardiomyopathy
- mutations
- metabolism